Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 14/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL234943 | 0.80 | CYP3A4 (0.58) | RAPGEF4CYP3A4CHRM1ALOX15MAOA | |
| SCHEMBL2972493 | 0.77 | CYP3A4 (0.55) | RAPGEF4CYP3A4CHRM1ALOX15MAOA | |
| SCHEMBL1314635 | 0.77 | CYP3A4 (0.55) | RAPGEF4CYP3A4CHRM1ALOX15MAOA | |
| SCHEMBL27561995 | 0.77 | CYP3A4 (0.55) | RAPGEF4CYP3A4CHRM1ALOX15MAOA | |
| SCHEMBL1005597 | 0.74 | CYP3A4 (0.46) | RAPGEF4CYP3A4CHRM1ALOX15MAOA | |
| SCHEMBL395136 | 0.72 | RAPGEF4 (0.39) | RAPGEF4TSHRALDH1A1MAPT | |
| SCHEMBL11876475 | 0.72 | RAPGEF4 (0.58) | RAPGEF4CYP3A4CHRM1ALOX15MAOA | |
| Sulfur Dioxide SCHEMBL10838499 | 0.70 | CYP3A4 (0.48) | RAPGEF4CYP3A4CHRM1ALOX15MAOA | |
| SCHEMBL28040382 | 0.70 | RAPGEF4 (0.38) | RAPGEF4TSHRALDH1A1MAPT | |
| SCHEMBL1003475 | 0.69 | CYP3A4 (0.46) | RAPGEF4CYP3A4CHRM1ALOX15MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140275463-A1 | ORGANOSILICON COMPOUND AND PRODUCTION PROCESS FOR THE SAME, AND POLYSILOXANE AND PRODUCTION PROCESS FOR THE SAME | CHISSO PETROCHEMICAL CORPORATION (JP) | 2014-09-18 | — | — | US | disclosed |
| EP-1548020-B1 | SILICON COMPOUND | JNC CORP (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8367792-B2 | Polysiloxane compound and method of producing the same | JNC CORPORATION (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120208973-A1 | POLYSILOXANE COMPOUND AND METHOD OF PRODUCING THE SAME | OOTAKE NOBUMASA (JP) | 2012-08-16 | — | — | US | disclosed |
| EP-1550664-B1 | SILICON COMPOUND | JNC CORP (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-8173758-B2 | Polysiloxane compound and method of producing the same | JNC CORPORATION (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20110178313-A1 | POLYSILOXANE COMPOUND AND METHOD OF PRODUCING THE SAME | OOTAKE NOBUMASA | 2011-07-21 | — | — | US | disclosed |
| US-7964692-B2 | Polymer obtained by addition-polymerization initiated by a silicon compound | JNC CORPORATION (JP) | 2011-06-21 | — | — | US | disclosed |
| US-7939617-B2 | Silsesquioxane derivative; electronic material, optical material, optoelectronic material, paint, and primer. | CHISSO CORPORATION (JP) | 2011-05-10 | — | — | US | disclosed |
| US-7863396-B2 | Silicon compounds | CHISSO CORPORATION (JP) | 2011-01-04 | — | — | US | disclosed |
| US-20050250925-A1 | Silicon compound | JNC CORPORATION (JP) | 2005-11-10 | — | — | US | disclosed |
| US-20050215807-A1 | Silsesquioxane derivative | JNC CORPORATION (JP) | 2005-09-29 | — | — | US | disclosed |
| EP-1550664-A1 | SILICON COMPOUND | CHISSO CORPORATION (JP) | 2005-07-06 | — | — | EP | disclosed |
| EP-1548020-A1 | SILICON COMPOUND | CHISSO CORPORATION (JP) | 2005-06-29 | — | — | EP | disclosed |
| US-20050033077-A1 | Production process for silicon compound and the same | JNC CORPORATION (JP) | 2005-02-10 | — | — | US | disclosed |
| US-20040249103-A1 | Silsesquioxane derivatives and process for production thereof | JNC CORPORATION (JP) | 2004-12-09 | — | — | US | disclosed |
| US-20040143081-A1 | Novel silicon compounds and process for preparation thereof | JNC CORPORATION (JP) | 2004-07-22 | — | — | US | disclosed |
| EP-1428795-A1 | SILSESQUIOXANE DERIVATIVES AND PROCESS FOR PRODUCTION THEREOF | CHISSO CORPORATION (JP) | 2004-06-16 | — | — | EP | disclosed |
| US-20040068074-A1 | Production process for silsesquioxane derivative having functional group and silsesquioxane derivative | JNC CORPORATION (JP) | 2004-04-08 | — | — | US | disclosed |
| US-20040030084-A1 | Production process for silsesquioxane derivative and silsesquioxane derivative | JNC CORPORATION (JP) | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178313-A1 | POLYSILOXANE COMPOUND AND METHOD OF PRODUCING THE SAME | RPS4X, POLR2A, MSL1 | RAPGEF4 4364/4885CYP3A4 1759/4885CHRM1 463/4885 |
| US-20140275463-A1 | ORGANOSILICON COMPOUND AND PRODUCTION PROCESS FOR THE SAME, AND POLYSILOXANE AND PRODUCTION PROCESS FOR THE SAME | PIEZO1, PFAS, MCM6 | RAPGEF4 4583/4885CYP3A4 1025/4885CHRM1 3739/4885 |
| US-20050215807-A1 | Silsesquioxane derivative | STS, SFXN1, SULT1A1 | RAPGEF4 4828/4885CYP3A4 515/4885CHRM1 3338/4885 |
| US-20120208973-A1 | POLYSILOXANE COMPOUND AND METHOD OF PRODUCING THE SAME | RPS4X, POLR2A, MSL1 | RAPGEF4 4364/4885CYP3A4 1759/4885CHRM1 463/4885 |
| US-20050033077-A1 | Production process for silicon compound and the same | STS, SMS, SFXN1 | RAPGEF4 4699/4885CYP3A4 690/4885CHRM1 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.